Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
78% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. OMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OMED' s Cash to Debt Range Over the Past 10 Years
Min: 326.31  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset -0.10
OMED's Equity to Asset is ranked lower than
93% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. OMED: -0.10 )
Ranked among companies with meaningful Equity to Asset only.
OMED' s Equity to Asset Range Over the Past 10 Years
Min: -2.45  Med: 0.25 Max: 0.7
Current: -0.1
-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
69% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -1.87
M-Score: -5.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -435.51
OMED's Operating margin (%) is ranked lower than
70% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. OMED: -435.51 )
Ranked among companies with meaningful Operating margin (%) only.
OMED' s Operating margin (%) Range Over the Past 10 Years
Min: -161.06  Med: -90.63 Max: -48.52
Current: -435.51
-161.06
-48.52
Net-margin (%) -434.74
OMED's Net-margin (%) is ranked lower than
71% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. OMED: -434.74 )
Ranked among companies with meaningful Net-margin (%) only.
OMED' s Net-margin (%) Range Over the Past 10 Years
Min: -152.47  Med: -90.09 Max: -47.87
Current: -434.74
-152.47
-47.87
ROE (%) -407.83
OMED's ROE (%) is ranked lower than
96% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. OMED: -407.83 )
Ranked among companies with meaningful ROE (%) only.
OMED' s ROE (%) Range Over the Past 10 Years
Min: -51.43  Med: -51.43 Max: -51.43
Current: -407.83
ROA (%) -46.03
OMED's ROA (%) is ranked lower than
67% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. OMED: -46.03 )
Ranked among companies with meaningful ROA (%) only.
OMED' s ROA (%) Range Over the Past 10 Years
Min: -28.05  Med: -20.49 Max: -12.61
Current: -46.03
-28.05
-12.61
ROC (Joel Greenblatt) (%) -1054.32
OMED's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. OMED: -1054.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1038.97  Med: -486.46 Max: -382.73
Current: -1054.32
-1038.97
-382.73
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

OMED Guru Trades in Q2 2015

Jim Simons 24,942 sh (New)
PRIMECAP Management 190,800 sh (-7.51%)
» More
Q3 2015

OMED Guru Trades in Q3 2015

Jim Simons 67,700 sh (+171.43%)
PRIMECAP Management 190,800 sh (unchged)
» More
Q4 2015

OMED Guru Trades in Q4 2015

PRIMECAP Management 191,800 sh (+0.52%)
Jim Simons Sold Out
» More
Q1 2016

OMED Guru Trades in Q1 2016

Paul Tudor Jones 14,800 sh (New)
First Eagle Investment 184,430 sh (New)
PRIMECAP Management 215,800 sh (+12.51%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:BSLN, NAS:MGNX, ROCO:4105, XKRX:003000, SZSE:300049, NAS:RGEN » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs.

OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.

Ratios

vs
industry
vs
history
P/S 19.53
OMED's P/S is ranked lower than
57% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. OMED: 19.53 )
Ranked among companies with meaningful P/S only.
OMED' s P/S Range Over the Past 10 Years
Min: 2.04  Med: 12.98 Max: 26.09
Current: 19.53
2.04
26.09
EV-to-EBIT -2.59
OMED's EV-to-EBIT is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. OMED: -2.59 )
Ranked among companies with meaningful EV-to-EBIT only.
OMED' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.4  Med: -8.00 Max: -0.3
Current: -2.59
-25.4
-0.3
EV-to-EBITDA -2.64
OMED's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. OMED: -2.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.6  Med: -8.25 Max: -0.3
Current: -2.64
-26.6
-0.3
Current Ratio 4.10
OMED's Current Ratio is ranked lower than
53% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. OMED: 4.10 )
Ranked among companies with meaningful Current Ratio only.
OMED' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 5.06 Max: 6.43
Current: 4.1
1.89
6.43
Quick Ratio 4.10
OMED's Quick Ratio is ranked lower than
52% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. OMED: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s Quick Ratio Range Over the Past 10 Years
Min: 1.89  Med: 5.06 Max: 6.43
Current: 4.1
1.89
6.43
Days Sales Outstanding 21.16
OMED's Days Sales Outstanding is ranked higher than
81% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. OMED: 21.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.22  Med: 59.49 Max: 65.72
Current: 21.16
0.22
65.72

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.50
OMED's Price/Median PS Value is ranked lower than
70% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. OMED: 1.50 )
Ranked among companies with meaningful Price/Median PS Value only.
OMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 1.04 Max: 2.02
Current: 1.5
0.19
2.02
Earnings Yield (Greenblatt) (%) -39.44
OMED's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. OMED: -39.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -81.3  Med: 0.00 Max: 0
Current: -39.44
-81.3
0

More Statistics

Revenue (TTM) (Mil) $22.56
EPS (TTM) $ -3.25
Beta2.07
Short Percentage of Float7.54%
52-Week Range $8.42 - 26.72
Shares Outstanding (Mil)30.30

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -3.43
EPS without NRI ($) -3.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
ETF’s with exposure to OncoMed Pharmaceuticals, Inc. : May 23, 2016 May 23 2016
OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
ONCOMED PHARMACEUTICALS INC Financials May 13 2016
OncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : OMED-US : May... May 09 2016
OncoMed reports 1Q loss May 05 2016
OncoMed reports 1Q loss May 05 2016
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results May 05 2016
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results May 05 2016
Q1 2016 OncoMed Pharmaceuticals Inc Earnings Release - Time Not Supplied May 05 2016
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5,... Apr 29 2016
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5,... Apr 29 2016
Big Pharma grooves $20 billion M&A dance with 2 Bay Area biotechs Apr 28 2016
AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion Apr 28 2016
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting Apr 21 2016
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting Apr 21 2016
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the... Apr 20 2016
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the... Apr 20 2016
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 Apr 19 2016
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 Apr 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)